[Biomarkers in inflammatory bowel disease].
Biomarcadores en enfermedad inflamatoria intestinal: ¿sabe cómo utilizarlos?
Journal
Revista medica de Chile
ISSN: 0717-6163
Titre abrégé: Rev Med Chil
Pays: Chile
ID NLM: 0404312
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
01
08
2019
accepted:
02
01
2020
entrez:
31
7
2020
pubmed:
31
7
2020
medline:
22
9
2020
Statut:
ppublish
Résumé
Biomarkers in inflammatory bowel disease are an essential tool in clinical practice. They allow a non-invasive evaluation of patients and thus guide decision-making at different stages of the disease, including diagnostic suspicion, severity assessment, relapse prediction, and treatment response. Although biomarkers in blood such as erythrocyte sedimentation rate and C-reactive protein, are the most commonly used biomarkers, because their low cost and accessibility, they lack specificity. Currently, fecal biomarkers offer greater reliability, applicability, and specificity. Fecal calprotectin is the most commonly used marker. This review discusses the advantages and disadvantages of biomarkers in inflammatory bowel disease, as well as their clinical applications and new biomarkers currently under research.
Identifiants
pubmed: 32730381
pii: S0034-98872020000300362
doi: 10.4067/S0034-98872020000300362
pii:
doi:
Substances chimiques
Biomarkers
0
Leukocyte L1 Antigen Complex
0
Types de publication
Journal Article
Review
Langues
spa
Sous-ensembles de citation
IM